Integrated DNA Technologies acquires oligo manufacturing business of GeneWorks
IDT expands its capacity for direct sales of genomic products in Asia-Pacific region.
Integrated DNA Technologies (IDT), through its Singapore subsidiary, has completed the acquisition of the oligonucleotide manufacturing business of GeneWorks Pty (GeneWorks) in Australia. This acquisition sees IDT expand its reach in the Asia-Pacific region, following its recent establishment of sales offices in Japan and Korea.
IDT offers GeneWorks' customers a broad range of manufacturing options for oligos, as well as other high-quality products for genomics research. GeneWorks will continue offering molecular and cell biology products and associated services. Both companies are committed to a seamless transition of the business for customers.
Dr Joseph A Walder, IDT founder and CEO, commented: “With this acquisition, we are furthering our goal of making our world-class products and services more easily accessible to scientists around the world. We look forward to availing GeneWorks’ customers of our unrivalled manufacturing capabilities, design expertise, and fast turnaround times.”
Peter Guilhaus, Managing Director of GeneWorks, agrees: “With IDT, our customers will continue to receive reliable oligo manufacturing and excellent customer service. We are pleased to begin the transitioning process and are confident our customers will find working with IDT to be efficient, easy, and cost-effective.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.